With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Is SIRT5 a Therapy Target in Acute Lymphoblastic Leukemia?||University of Utah / Michael Deininger, MD/PhD||Innovation Grants||2018||Utah|
|The TC3 Line, a Zebrafish Model of T-Cell Malignancy||Huntsman Cancer Institute / Nathan Meeker, MD||Young Investigator Grants||2008||Utah|
|Identification of predisposition genes for Ewing sarcoma segregating in high-risk pedigrees||Huntsman Cancer Institute / Lisa Cannon-Albright, PhD||Innovation Grants||2012||Utah|
|Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma||University of Virginia, School of Medicine / John Bushweller, PhD||Innovation Grants||2015||Virginia|
|Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma||Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP)||Innovation Grants||2015||Virginia|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Virginia, School of Medicine / Michael Engel, MD/PhD||Reach Grants||2016||Virginia|
|Critical Contributions of CRM1 to Leukemogenesis||University of Vermont / Jessica Linda Heath, MD||Young Investigator Grants||2015||Vermont|
|TrkB Signaling in the Genesis of Murine Neuroblastoma||University of Vermont / Rae Nishi, PhD||Innovation Grants||2007||Vermont|
|Serious Morbidity and Financial Outcomes Among Pediatric Cancer Survivors||Fred Hutchinson Cancer Research Center / Beth Mueller, PhD||Epidemiology Grants||2014||Washington|
|Use sophisticated approaches to optimize the effectiveness of current chemotherapy agents, and to develop novel chemotherapy agents||Seattle Children's Hospital and Regional Medical Center / Julie Park, MD||Phase I/II Infrastructure Grants||2006||Washington|